Processa Pharmaceuticals, Inc. (PCSA)
Data as of , from SEC Form 4 filings.
See up to 3 months of PCSA. The 7-day demo opens the 1M and 3M ranges and puts PCSA on your watchlist.
Start 7-day demoLatest PCSA insider trades
Wendy Guy - OfficerOpen-market purchase$5K- Patrick Lin - OfficerOpen-market purchase
About Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
- VERO BEACH, FL
- 12
- 2013
- XNAS
https://www.processapharmaceuticals.comSEC filings for PCSA on EDGAR
PCSA Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 10 | 285,011 | |
| Option exercise | 2 | 3,200 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
PCSA insider transactions (Form 4)
2481 Form 4 filings on record, the earliest from Jul 24, 2025, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| James R. Neal | Grant or award | Restricted Stock Units | 100,000 | $0.00 | - | |
| James R. Neal | Grant or award | Stock Options (Right to Buy) | 300,000 | $0.00 | - | |
 Khoso Baluch | Grant or award | Restricted Stock Units | 100,000 | $0.00 | - | |
| Khoso Baluch | Grant or award | Stock Options (Right to Buy) | 300,000 | $0.00 | - | |
| Geraldine Pannu | Grant or award | Restricted Stock Units | 100,000 | $0.00 | - | |
| Geraldine Pannu | Grant or award | Stock Options (Right to Buy) | 300,000 | $0.00 | - | |
| Wendy Guy - Officer | Grant or award | Restricted Stock Units | 50,000 | $0.00 | - | |
| Wendy Guy - Officer | Grant or award | Stock Options (Right to Buy) | 150,000 | $0.00 | - | |
| Patrick Lin - Officer | Grant or award | Restricted Stock Units | 68,000 | $0.00 | - | |
| Patrick Lin - Officer | Grant or award | Stock Options (Right to Buy) | 204,000 | $0.00 | - | |
 Sian Bigora - Officer | Grant or award | Restricted Stock Units | 96,000 | $0.00 | - | |
| Sian Bigora - Officer | Grant or award | Stock Options (Right to Buy) | 288,000 | $0.00 | - | |
| George K. Ng - Officer | Grant or award | Restricted Stock Units | 256,000 | $0.00 | - | |
| George K. Ng - Officer | Grant or award | Stock Options (Right to Buy) | 768,000 | $0.00 | - | |
| David Young - Officer | Grant or award | Restricted Stock Units | 111,000 | $0.00 | - | |
| David Young - Officer | Grant or award | Stock Options (Right to Buy) | 333,000 | $0.00 | - | |
| Justin W. Yorke | Grant or award | Restricted Stock Units | 100,000 | $0.00 | - | |
| Justin W. Yorke | Grant or award | Stock Options (Right to Buy) | 300,000 | $0.00 | - | |
 Russell Skibsted - Officer | Grant or award | Restricted Stock Units | 108,000 | $0.00 | - | |
| Russell Skibsted - Officer | Grant or award | Stock Options (Right to Buy) | 324,000 | $0.00 | - | |
| Wendy Guy - Officer | Grant or award | Restricted Stock Units | 1,366,046 | $0.00 | - | |
| Geraldine Pannu | Grant or award | Restricted Stock | 31,206 | $0.00 | - | |
| James R. Neal | Grant or award | Restricted Stock | 31,206 | $0.00 | - | |
| Khoso Baluch | Grant or award | Restricted Stock | 31,206 | $0.00 | - |
PCSA insider trading FAQ
What is the latest insider trade for PCSA?
Processa Pharmaceuticals, Inc. (PCSA) had 10 insider filings in the last 90 days, with the most recent on 2026-08-11. The full record for PCSA runs to 81 Form 4 filings, the earliest from 2025-07-24. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying PCSA stock?
No insider purchases of PCSA were filed in the last 90 days. 42 purchases are on record for this company.
How many insiders are selling PCSA stock?
No insider sales of PCSA were filed in the last 90 days.
Where can I see PCSA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects PCSA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - George K. Ng view on EDGAR
- - Sheila Gujrathi view on EDGAR
- - Justin W. Yorke view on EDGAR
- - Russell Skibsted view on EDGAR
- - Geraldine Pannu view on EDGAR
- - George K. Ng view on EDGAR
- - James R. Neal view on EDGAR
- - Patrick Lin view on EDGAR
- - Wendy Guy view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where PCSA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow PCSA with a 7-day demo
- PCSA on your watchlist
- Every PCSA Form 4 filing on record
- Up to 3 months of PCSA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
